Worldwide antimicrobial susceptibility patterns among E. coli isolated from intra-abdominal infections (IAI): results from SMART 2005
Abstract number: 1733_161
Gallagher G., Hsueh P.R., Baquero F., Paterson D., Báez-Villaseñor J., Wilson H., Abramson M.
Background: SMART (Study for Monitoring Antimicrobial Resistance Trends) is an ongoing global antimicrobial surveillance programme focused on clinical isolates from intra-abdominal infections (IAI). The aim of the 2005 analysis was to assess antimicrobial susceptibility patterns among E. coli from 5 different regions of the world.
Methods: 48 centres in the North America (NA), Latin America (LA), Europe (EU), Middle East/Africa (ME/A), & Asia/Pacific (A/P) tested the in vitro activity of 12 antimicrobial agents Microdilution techniques followed CLSI guidelines. E. coli were screened for extended-spectrum b-lactamase (ESBL) production by ceftriaxone, cefotaxime, cefepime, or ceftazidime MIC greater than or equal to 2 ug/mL & confirmed by comparing ceftazidime, cefotaxime, and cefepime MICs ± clavulanate.
Results:E. coli was recovered from 1852 patients of the study's 3553 patients (3805 isolates) worldwide. % susceptibilities are reported by region in the table. ESBL-producing E. coli constituted 1%, 9%, 4%, 9%, & 21% of isolates from NA, LA, EU, ME/A, & A/P, respectively. 53% (979/1852) were recovered <48 hrs of hospitalisation. Of those, 3% (32/979) were ESBL producers.
Conclusion: Prevalence of ESBL-producing strains may affect choice of empirical therapy. Many ESBL-producing E. coli may have been hospital acquired. Overall, ertapenem, imipenem, and amikacin were the most reliably active drugs in vitro against E. coli.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|